ARMATA PHARMACEUTICALS, INC. Operating Lease, Expense
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Operating Lease, Expense of $1.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-06-30 was $1.80M, a 10.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2026-03-31 was $1.80M, a 10.00% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-12-31 was $2.00M, a 4.76% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for the quarter ending 2025-09-30 was $2.00M, a 0.00% change year-over-year.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for fiscal 2025 was $8.00M, a 4.76% decline from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for fiscal 2024 was $8.40M, a 13.51% increase from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for fiscal 2023 was $7.40M, a 17.46% increase from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. operating lease, expense for fiscal 2022 was $6.30M, a 133.33% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.80M 10-Q · filed 2026-08-12 | $3.60M 10-Q · filed 2026-08-12 | $5.60M derived: sum of 3 quarters · filed 2026-08-12 | $7.60M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.80M 10-Q · filed 2026-05-13 | $3.80M derived: sum of 2 quarters · filed 2026-05-13 | $5.80M derived: sum of 3 quarters · filed 2026-05-13 | $7.80M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.00M derived: sum of 2 quarters · filed 2026-03-25 | $6.00M derived: sum of 3 quarters · filed 2026-08-12 | $8.00M 10-K · filed 2026-03-25 |
| 2025-09-30 | $2.00M 10-Q · filed 2025-11-12 | $4.00M derived: sum of 2 quarters · filed 2026-08-12 | $6.00M 10-Q · filed 2025-11-12 | $8.10M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $2.00M 10-Q · filed 2026-08-12 | $4.00M 10-Q · filed 2026-08-12 | $6.10M derived: sum of 3 quarters · filed 2026-08-12 | $8.10M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.00M 10-Q · filed 2026-05-13 | $4.10M derived: sum of 2 quarters · filed 2026-05-13 | $6.10M derived: sum of 3 quarters · filed 2026-05-13 | $8.10M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | $4.10M derived: sum of 2 quarters · filed 2026-03-25 | $6.10M derived: sum of 3 quarters · filed 2026-03-25 | $8.40M 10-K · filed 2026-03-25 |
| 2024-09-30 | $2.00M 10-Q · filed 2025-11-12 | $4.00M derived: sum of 2 quarters · filed 2025-11-12 | $6.30M 10-Q · filed 2025-11-12 | $7.90M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $2.00M 10-Q · filed 2025-08-12 | $4.20M 10-Q · filed 2025-08-12 | $5.90M derived: sum of 3 quarters · filed 2025-08-12 | $8.00M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.20M 10-Q · filed 2025-05-14 | $3.90M derived: sum of 2 quarters · filed 2025-05-14 | $6.00M derived: sum of 3 quarters · filed 2025-05-14 | $7.80M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $3.80M derived: sum of 2 quarters · filed 2025-03-21 | $5.60M derived: sum of 3 quarters · filed 2025-03-21 | $7.40M 10-K · filed 2025-03-21 |
| 2023-09-30 | $2.10M 10-Q · filed 2024-11-13 | $3.90M derived: sum of 2 quarters · filed 2024-11-13 | $5.70M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $1.80M 10-Q · filed 2024-08-13 | $3.60M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $1.80M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $6.30M 10-K · filed 2024-03-21 | |||
| 2021-12-31 | $2.70M 10-K · filed 2023-03-16 | |||
| 2020-12-31 | $1.90M 10-K · filed 2022-03-17 | |||
| 2019-12-31 | $1.50M 10-K · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |